Teichomycin A2
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-03493 |
| CAS | 61036-64-4 |
| Molecular Weight | 1921.70 |
| Molecular Formula | C90H99Cl2N9O34 |
| Purity | 95% |
Online Inquiry
Description
Teichomycin A2 is a glycopeptide antibiotic produced by Actinoplanes teichomyceticus nov. sp. (ATTCC 31121). Activity against gram-positive bacteria.
Specification
| Synonyms | Teicoplanin A2; Teichomycin A2; MDL-507; Targocid; Targosid |
| IUPAC Name | methyl 2-[3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-amino-5,15-dichloro-64-[3-[[(E)-dec-4-enoyl]amino]-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,26,31,44,49-pentahydroxy-30-methyl-21,35,38,54,56,59-hexaoxo-47-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14,16,23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,62,65-henicosaene-52-carboxylate |
| Canonical SMILES | CCCCCC=CCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=C(C(=CC(=C7)O)OC8C(C(C(C(O8)CO)O)O)O)C9=C(C=CC(=C9)C(C(=O)N6)NC(=O)C4NC(=O)C1C2=CC(=C(C(=C2)OC2=C(C=CC(=C2)C(C(=O)NC(C(C2=CC(=C(O3)C=C2)Cl)O)C(=O)N1)N)O)C)O)O)C(=O)OC)OC1C(C(C(C(O1)CO)O)O)NC(=O)C)Cl)CO)O)O |
| InChI | InChI=1S/C90H99Cl2N9O34/c1-5-6-7-8-9-10-11-12-60(110)95-69-76(116)73(113)58(32-103)132-89(69)135-80-55-27-41-28-56(80)128-51-20-16-39(23-46(51)92)79(134-88-68(94-35(3)105)75(115)72(112)57(31-102)131-88)70-86(124)99-66(87(125)126-4)44-29-42(106)30-54(130-90-78(118)77(117)74(114)59(33-104)133-90)61(44)43-21-37(14-17-47(43)107)63(82(120)101-70)96-84(122)65(41)97-83(121)64-40-24-49(109)34(2)52(26-40)129-53-25-36(13-18-48(53)108)62(93)81(119)100-67(85(123)98-64)71(111)38-15-19-50(127-55)45(91)22-38/h9-10,13-30,57-59,62-79,88-90,102-104,106-109,111-118H,5-8,11-12,31-33,93H2,1-4H3,(H,94,105)(H,95,110)(H,96,122)(H,97,121)(H,98,123)(H,99,124)(H,100,119)(H,101,120)/b10-9+ |
| InChI Key | LCTCUBQFWLTHNS-MDZDMXLPSA-N |
Properties
| Appearance | White Powder |
| Application | Anti-Bacterial Agents |
| Antibiotic Activity Spectrum | Gram-positive bacteria |
| Melting Point | >180°C (dec.) |
| Density | 1.7±0.1 g/cm3 |
| Solubility | Soluble in DMSO, Water |
Reference Reading
1.Risk factors assessment for nasal colonization of Staphylococcus aureus and its methicillin resistant strains among pre-clinical medical students of Nepal.
Ansari S1, Gautam R2, Shrestha S2, Ansari SR3, Subedi SN4, Chhetri MR4. BMC Res Notes. 2016 Apr 12;9(1):214. doi: 10.1186/s13104-016-2021-7.
BACKGROUND: Staphylococcus aureus (S. aureus), a normal flora of nasal cavity, can cause minor to life threatening invasive diseases and nosocomial infections. Methicillin resistant strains of S. aureus are causing a great challenge for treatment options. Therefore, the purpose of this study was to assess the nasal carriage rate of S. aureus, its methicillin resistant strains and risk factors in medical students prior to clinical exposure.
2.Retrospective study of teicoplanin loading regimen that rapidly achieves target 15-30 μg/mL serum trough concentration.
Kato H1, Hamada Y1, Hagihara M1, Hirai J2, Nishiyama N2, Koizumi Y2, Yamagishi Y2, Matsuura K3, Mikamo H4. J Infect Chemother. 2016 May;22(5):308-13. doi: 10.1016/j.jiac.2016.01.019. Epub 2016 Mar 5.
OBJECTIVES: There are several studies of assessment for teicoplanin loading dose regimen. However, the optimal loading dose achieving the target range 15-30 μg/mL has been still unclear. We investigated the probability of target attachment as teicoplanin concentration 15-30 μg/mL at the 3rd day after teicoplanin therapy started, clinical efficacy and safety in retrospective study.
3.Detection of Vancomycin Resistance among Enterococcus faecalis and Staphylococcus aureus.
Rengaraj R1, Mariappan S2, Sekar U3, Kamalanadhan A4. J Clin Diagn Res. 2016 Feb;10(2):DC04-6. doi: 10.7860/JCDR/2016/17552.7201. Epub 2016 Feb 1.
INTRODUCTION: Vancomycin remains the drug of choice for resistant gram positive infections caused by Enterococcus spp and Methicillin resistant Staphylococcus aureus (MRSA). Increased use of vancomycin has led to frank resistance and increase in MIC (MIC creep). Vancomycin intermediate Staphylococcus aureus (VISA), Vancomycin resistant Staphylococcus aureus (VRSA) & Vancomycin resistant Enterococci (VRE) are important emerging nosocomial pathogens resulting in treatment failures.
4.Draft Genome Sequence of a Vancomycin-Resistant and Vancomycin-Dependent Enterococcus faecium Isolate.
Blaschitz M1, Lepuschitz S1, Wagner L1, Allerberger F1, Indra A1, Ruppitsch W2, Huhulescu S1. Genome Announc. 2016 Apr 7;4(2). pii: e00059-16. doi: 10.1128/genomeA.00059-16.
Vancomycin-resistant enterococci have emerged as major nosocomial pathogens worldwide. While antimicrobial pressure promotes nosocomial colonization with these enterococci, prolonged exposure to vancomycin may foster the transition from vancomycin resistance to vancomycin dependence. Here, we report the draft genome sequence of a vancomycin-dependentEnterococcus faeciumisolate showing partial teicoplanin dependence.
Recommended Products
| BBF-01825 | Loganin | Inquiry |
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-03755 | Actinomycin D | Inquiry |
| BBF-03754 | Castanospermine | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
